Christian Schmidt

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski, Ariel Perez Perez, Pierre Sesques et al. · Blood · 2021 · 398 citations · Full text

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski et al. · The Lancet · 2016 · 390 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

Eva Hoster, Andreas Rosenwald, Françoise Berger et al. · Journal of Clinical Oncology · 2016 · 344 citations

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

Norbert Schmitz, Maike Nickelsen, Marita Ziepert et al. · The Lancet Oncology · 2012 · 247 citations

Hematological Malignancy, Lymphoid Neoplasia, Conventional Chemotherapy +8

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 244 citations · Full text